New pill shows promise for scarred lungs in early trial
Disease control
Completed
This Phase 2 study tested an experimental oral drug called TTI-101 in 100 people with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing difficulty. Participants took either TTI-101 or a placebo daily for 12 weeks. The main goal was to check sa…
Phase: PHASE2 • Sponsor: Tvardi Therapeutics, Incorporated • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC